参考来源:
1、 UPDATED: Biogen makes another bold Alzheimer’s bet, dropping $350M upfront to partner with genome-editing focused Sangamo
2、 Biogen, Sangamo look to tackle Alzheimer's, Parkinson's through gene regulation
3、 BIOGEN AND SANGAMO ANNOUNCE GLOBAL COLLABORATION TO DEVELOP GENE REGULATION THERAPIES FOR ALZHEIMER’S, PARKINSON’S, NEUROMUSCULAR, AND OTHER NEUROLOGICAL DISEASES
*声明:本文由入驻新浪医药新闻作者撰写,观点仅代表作者本人,不代表新浪医药新闻立场。